Global Retirement Partners’s Intellia Therapeutics NTLA Stock Holding History

Global Retirement Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.94K	Buy	216 +125	+137%	+$1.72K	﹤0.01%	3741
2025 Q3	$1.57K	Buy	91 +24	+36%	+$296	﹤0.01%	3390
2025 Q2	$628	Buy	+67	New	+$550	﹤0.01%	3546
2024 Q4	$8.96K	Buy	768 +664	+638%	+$10.4K	﹤0.01%	2435
2024 Q3	$2.14K	Hold	104	–	–	﹤0.01%	2913
2024 Q2	$2.33K	Buy	104 +41	+65%	+$976	﹤0.01%	2915
2024 Q1	$1.73K	Sell	63 -4	-6%	-$111	﹤0.01%	2799
2023 Q4	$1.79K	Buy	67 +1	+2%	+$29	﹤0.01%	2717
2023 Q3	$1.91K	Sell	66 -4	-6%	-$155	﹤0.01%	2557
2023 Q2	$2.85K	Hold	70	–	–	﹤0.01%	2410
2023 Q1	$2.7K	Buy	70 +7	+11%	+$275	﹤0.01%	2393
2022 Q4	$2.2K	Hold	63	–	–	﹤0.01%	2327
2022 Q3	$3K	Hold	63	–	–	﹤0.01%	2127
2022 Q2	$3K	Hold	63	–	–	﹤0.01%	2085
2022 Q1	$3K	Buy	+63	New	+$5.34K	﹤0.01%	2077

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Global Retirement Partners's NTLA Position: Q4 2025 in Review

Global Retirement Partners increased its Intellia Therapeutics (NTLA) stake by 137% in Q4 2025, buying an estimated $1.72K and bringing the position to 216 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #3741.

Global Retirement Partners first reported a position in NTLA in Q1 2022 and has held it in 15 quarters since. The position peaked at $8.96K in Q4 2024. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

Global Retirement Partners held 216 shares of Intellia Therapeutics worth $1.94K as of Q4 2025.
Global Retirement Partners bought 125 Intellia Therapeutics shares in Q4 2025, an estimated $1.72K.
Intellia Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2025, its #3741 holding.
Global Retirement Partners first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 15 quarters since.
Global Retirement Partners's Intellia Therapeutics position peaked at $8.96K in Q4 2024.
291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Global Retirement Partners's 13F filing for Q4 2025, filed 6 Feb 2026.